Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Concurrent chemoradiotherapy is the standard treatment for locally advanced, unresectable
non-small cell lung cancer, but carries a risk of radiation pneumonitis of approximately 30%,
and is associated with a decline in pulmonary quality of life.
Standard radiation planning aims to optimize dose to the anatomic lung volume, without
consideration of the differences in regional lung function. Functional lung avoidance
radiotherapy aims to reduce radiotherapy dose to regions of functioning lung, instead
depositing dose in areas of lung that are not well-ventilated. Functional lung regions are
determined using noble-gas MRI and co-registered to the radiotherapy planning CT scans.
Functional lung avoidance radiotherapy has been demonstrated to be feasible, and this trial
aims to compare outcomes between standard radiotherapy (with concurrent chemotherapy) vs.
functional lung avoidance radiotherapy (with concurrent chemotherapy).